Trial Profile
A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Tepotinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck KGaA
- 01 Jul 2022 Results of a pooled exposure-efficacy analyses included data from an ongoing phase 2 study (VISION) and 4 completed studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations published in the Cancer Chemotherapy and Pharmacology
- 10 May 2021 Results published in the British Journal of Cancer
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.